You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

Drug Price Trends for FT NASAL DECONG PE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for FT NASAL DECONG PE

Average Pharmacy Cost for FT NASAL DECONG PE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
FT NASAL DECONG PE 10 MG TAB 70677-1152-01 0.05327 EACH 2025-01-22
FT NASAL DECONG PE 10 MG TAB 70677-1152-02 0.05327 EACH 2025-01-22
FT NASAL DECONG PE 10 MG TAB 70677-1152-01 0.05120 EACH 2024-12-18
FT NASAL DECONG PE 10 MG TAB 70677-1152-02 0.05120 EACH 2024-12-18
FT NASAL DECONG PE 10 MG TAB 70677-1152-02 0.05150 EACH 2024-11-20
FT NASAL DECONG PE 10 MG TAB 70677-1152-01 0.05150 EACH 2024-11-20
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Nasal Decongestants: The Case of Oral Phenylephrine

Introduction

The market for nasal decongestants is a significant segment within the pharmaceutical industry, driven by the widespread need for relief from nasal congestion due to various respiratory conditions. This article will focus on the current status, market analysis, and future projections of nasal decongestants, particularly highlighting the controversies and developments surrounding oral phenylephrine.

Market Overview of Nasal Decongestants

The global decongestants market is projected to reach $21.3 billion by 2027, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period 2022-2027[2].

Geographical Distribution

North America holds the largest market share, accounting for 40% of the overall market in 2021. This dominance is attributed to the high sales of decongestants, including those containing phenylephrine and pseudoephedrine, as well as the increasing use of over-the-counter ocular decongestants in the U.S. and Canada[2].

Market Segmentation

The decongestants market is segmented by application into hospitals, clinics, research and academic laboratories, and others. Hospitals held the largest market share in 2021, driven by the increasing inclination of patients towards hospital diagnosis for conditions like the common cold and allergic rhinitis[2].

The Role of Oral Phenylephrine

Oral phenylephrine has been a widely used ingredient in over-the-counter (OTC) cold and allergy medications since the restriction of pseudoephedrine in 2006.

Historical Context and FDA Review

Initially recognized as "generally recognized as safe and effective" (GRASE) in 1976, oral phenylephrine's efficacy has been under scrutiny. In 2007, the FDA Advisory Committee recommended further clinical data to evaluate its safety and effectiveness. A subsequent meeting in September 2023 concluded that current scientific data do not support the effectiveness of oral phenylephrine as a nasal decongestant at its recommended dose[1][5].

Safety and Efficacy Concerns

The FDA advisory committee's unanimous vote (16-0) against the efficacy of oral phenylephrine marked a significant shift. While the medication is considered safe, its lack of proven benefit raises questions about its continued use. The FDA may initiate a process to remove oral phenylephrine's GRASE status, which would lead to its removal from the market[1][5].

Market Impact of FDA Findings

The potential removal of oral phenylephrine from the market could significantly impact the decongestants market.

Alternative Products

Consumers may turn to alternative decongestants such as oxymetazoline nasal sprays (e.g., Afrin®), pseudoephedrine tablets (e.g., Sudafed®), or phenylephrine nasal sprays (e.g., Neo-Synephrine®), which have different routes of administration and specific sites of action[5].

Market Growth Drivers

Despite the controversy surrounding oral phenylephrine, the decongestants market is expected to grow driven by factors such as:

  • Surging applications of decongestants for alleviating nasal congestion.
  • Increasing use of nasal sprays due to their ease of administration and faster performance.
  • Growing prevalence of respiratory diseases and seasonal allergies.
  • Innovations in drug delivery systems and packaging[2][3].

Price Projections and Market Trends

The decongestants market, including nasal sprays and other forms, is expected to see steady growth.

Nasal Spray Market

The nasal spray bottle market is projected to grow from $14.88 billion in 2023 to $15.70 billion in 2024 at a CAGR of 5.5%. By 2028, it is expected to reach $19.55 billion, driven by the growing demand for non-invasive drug delivery methods and technological advancements in spray technology[3].

Nasal Drug Delivery Technology

The global nasal drug delivery technology market is expected to grow from approximately $4.4 billion in 2024 to around $7.8 billion by 2031, achieving a CAGR of about 8.4%. This growth is driven by the increasing demand for non-invasive administration methods and advancements in delivery technologies[4].

Regional Growth and Trends

  • North America: Expected to continue dominating the market due to high sales of decongestants and the surging application of nasal sprays.
  • Asia-Pacific: Projected to grow with the fastest CAGR over the forecast period, driven by the increasing use of decongestants for alleviating nasal congestion and the growing prevalence of respiratory diseases[2].

Key Takeaways

  • The decongestants market is growing, driven by increasing demand and technological advancements.
  • Oral phenylephrine's efficacy as a nasal decongestant is under question, with potential removal from the market.
  • Alternative decongestants and nasal sprays are expected to fill the gap.
  • Regional markets, especially North America and the Asia-Pacific, will continue to drive market growth.

FAQs

What is the current status of oral phenylephrine as a nasal decongestant?

Oral phenylephrine's efficacy as a nasal decongestant has been questioned by the FDA, with recent advisory committee findings concluding that it is not effective at its recommended dose.

What alternatives are available for nasal congestion relief?

Alternatives include oxymetazoline nasal sprays, pseudoephedrine tablets, and phenylephrine nasal sprays, each with different administration routes and specific sites of action.

How is the decongestants market expected to grow in the coming years?

The decongestants market is expected to reach $21.3 billion by 2027, growing at a CAGR of 6.3%, driven by surging applications and technological advancements.

What are the key drivers of the nasal spray market growth?

Key drivers include the growing demand for non-invasive drug delivery methods, technological advancements in spray technology, and increasing use of self-medication.

How does the FDA's decision on oral phenylephrine impact the market?

The potential removal of oral phenylephrine could lead to increased sales of alternative decongestants and nasal sprays, as consumers seek effective relief from nasal congestion.

Sources

  1. FDA: Current Status of Oral Phenylephrine as a Nasal Decongestant - FDA.
  2. IndustryARC: Decongestants Market Size Report, 2022-2027.
  3. The Business Research Company: Nasal Spray Bottle Global Market Report 2024.
  4. PR Newswire: Nasal Drug Delivery Technology Market Breakthrough in Patient Care Projected Market Growth to USD 7.8 Billion by 2031.
  5. Parkview Health: Are popular decongestants being pulled off the market?

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.